Expression and localization of P-glycoprotein in human heart: Effects of cardiomyopathy

Journal of Histochemistry and Cytochemistry

Volumn 50, Issue 10, 2002, Pages 1351-1356

  Meissner, Konrad ^a   Sperker, Bernhard ^a   Karsten, Christiane ^a   Zu Schwabedissen, Henriette Meyer ^a   Seeland, Ute ^a   Böhm, Michael ^a   Bien, Sandra ^a   Dazert, Peter ^a   Kunert Keil, Christiane ^a   Vogelgesang, Silke ^a   Warzok, Rolf ^a   Siegmund, Werner ^a   Cascorbi, Ingolf ^a   Wendt, Michael ^a   Kroemer, Heyo K ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Cardiomyopathy; Drug transport; Heart; P glycoprotein

Indexed keywords

ABC TRANSPORTER; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIAC GLYCOSIDE; DOXORUBICIN; GLYCOPROTEIN P; XENOBIOTIC AGENT;

ARTERIOLE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; HEART; HEART DILATATION; HEART LEFT VENTRICLE; HEART MUSCLE CAPILLARY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIUM;

EID: 18644370534     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1177/002215540205001008     Document Type: Article

References (27)

1. Agarwala S, Kumar R, Bhatnagar V, Bajpai M, Gupta DK, Mitra DK (2000) High incidence of adriamycin cardiotoxicity in children even at low cumulative doses: role of radionuclide cardiac angiography. J Pediatr Surg 35:1786-1789
2. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, et al. (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169-174
3. de Lannoy IA, Silverman M (1992) The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 189:551-557
4. Dobbs RJ, Royston JP, O'Neill CJ, Deshmukh AA, Nicholson PW, Denham MJ, Dobbs SM (1987) Prescribing digoxin in geriatric units: the unexplained variability in dosage requirements. Eur J Clin Pharmacol 32:611-614
5. Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M, Zojer N, et al. (1996) Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 88:1747-1754
6. Fardel O, Lecureur V, Daval S, Corlu A, Guillouzo A (1997) Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Eur J Biochem 246:186-192
7. Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, Eichelbaum M, et al. (2000) The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 157:1575-1580
8. Geick A, Eichelbaum M, Burk O (2001) Nuclear receptor response elements mediate induction of intestinal mdr1 by rifampin. J Biol Chem 276:14581-14587
9. Goorin AM, Chauvenet AR, Perez-Atayde AR, Cruz J, McKone R, Lipshultz SE (1990) Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 116:144-147
10. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147-153
11. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478
12. Jette L, Tetu B, Beliveau R (1993) High levels of P-glycoprotein detected in isolated brain capillaries. Biochim Biophys Acta 1150:147-154
13. Karlsson J, Kuo SM, Ziemniak J, Artursson P (1993) Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br J Pharmacol 110:1009-1016
14. Kawahara M, Sakata A, Miyashita T, Tamai I, Tsuji A (1999) Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. J Pharmacol Sci 88:1281-1287
15. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808-815
16. Podlowski S, Luther HP, Morwinski R, Muller J, Wallukat G (1998) Agonistic anti-beta1-adrenergic receptor autoantibodies from cardiomyopathy patients reduce the beta1-adrenergic receptor expression in neonatal rat cardiomyocytes. Circulation 98:2470-2476
17. Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS (1989) Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 81:696-701
18. Schinkel AH (1997) The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 8:161-170
19. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, et al. (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94:4028-4033
20. Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524
21. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, et al. (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137-1143
22. Thum T, Borlak J (2000) Gene expression in distinct regions of the heart. Lancet 355:979-983
23. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C (1995) MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36:1-6
24. van Asperen J, van Tellingen O, Tijssen F, Schinkel AH, Beijnen JH (1999) Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdrla P-glycoprotein. Br J Cancer 79:108-113
25. Vogelgesang S, Schroeder E, Runge U, Gaab MR, Piek J, Cascorbi I, Siegmund W, et al. (2001) Expression of P-glycoprotein in medically intractable epilepsy. Acta Neuropathol (Berl) 102:545
26. Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, et al. (2000) Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 68:6-12
27. Wijnholds J, Evers R, van Leusden MR, Mol CA, Zaman GJ, Mayer U, Beijnen JH, et al. (1997) Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nature Med 3:1275-1279